secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2026-05-21T20:06:17+00:00
Accession:  0001171843-26-003617
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics targets Q2 2027 commercialization for Mint patch pump
------------------------------------------------------------------

- Expects full commercialization of Mint patch pump by end of Q2 2027, subject to FDA clearance.
- Timeline based on FDA initial responses to 510(k) ACE insulin pump application and manufacturing scale progress.
- Mint features: 200-unit reservoir, 3-day wear, waterproof, smartphone controlled, no recharging needed.
- Compatible with Beta Bionics' iAGC algorithm and Dexcom G7, Abbott FreeStyle Libre 3 Plus CGMs.
- Exclusively available in pharmacy channel; manufacturing capacity expected to meet launch demand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326003617/0001171843-26-003617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326003617/f8k_052126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer